International Conference Features UCSF Breast Cancer Experts

2 pm to 3 pm CT

Translational Controversies: RIP MTD (maximum tolerated dose)

Hope S. Rugo, MD, is a featured speaker on a discussion session panel addressing translational controversies. She will be discussing the rethinking of the concept of the maximum tolerated dose for breast cancer treatment. Rugo is a professor of medicine in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and director of Breast Oncology and Clinical Trials Education.

7 am to 8:15 am CT

Improving Outcome for TNBC: New Directions in Immunotherapy

Hope S. Rugo, MD, will chair this session about new treatment strategies for triple negative breast cancer. Discussion topics include enhancing immune response in HER2 negative breast cancer, immunotherapy combinations and corrective markers, and enhancing the effects of immunotherapy in metastatic breast cancer.

5 pm to 6:15 pm CT

Exposure-Adjusted Incidence Rates (EAIRs) of Adverse Events (AEs) from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in HR+/HER2-Metastatic Breast Cancer (MBC)

Hope S. Rugo, MD, is the senior author and presenter of this study which reports on the favorable risk/benefit profile for sacituzumab govitecan (SG) compared with standard chemotherapy in a patient population with limited therapeutic options. Abstract P3-07-08

7 am to 8:15 am CT

Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer from BYLieve Study Cohorts A and B

Hope S. Rugo, MD, is the senior author and presenter of this study which reports the results of a biomarker analysis using paired baseline (Cycle 1 Day 1) and end-of-treatment (EOT) circulating tumor DNA (ctDNA) samples from patients in BYLieve Cohorts A and B. Abstract P4-09-12

12:30 pm to 12:45 pm CT

Evaluation of Anti-PD-1 Cemiplimab Plus Anti-LAG-3 REGN3767 in Early-Stage, High-Risk HER2-Negative Breast Cancer: Results from the Neoadjuvant I-SPY 2 TRIAL

Laura Esserman, MD, MBA, is senior author of this study which is one of several I-SPY 2 study abstracts being reported on at SABCS. This session will address the efficacy of Cemiplimab in a phase 3 neoadjuvant trial. Esserman is a UCSF professor of surgery and radiology, director of the UCSF Breast Care Center and principal investigator of the ISPY 2 trials. Abstract GS5-03

12:45 pm to 1 pm CT

Identification of Symptoms That Are Associated With irAEs in the I-SPY Clinical Trial

Amrita Basu, PhD, is first author and presenter of this study which utilizes an analysis framework to determine symptom clusters that predict the development of irAEs (immune-related adverse events). She will describe specific symptoms presenting early with the development of hypothyroidism and adrenal insufficiency. Basu is an assistant professor of surgery at UCSF. Abstract GS5-04

2:15 pm to 2:30 pm CT

Utility of the 70-Gene MammaPrint Test for Prediction of Extended Endocrine Therapy Benefit in Patients With Early-Stage Breast Cancer in the IDEAL Trial

Laura J. van ’t Veer, PhD, is the senior author and presenter for this session which explores extended endocrine treatment (EET) for MammaPrint Low tumors and the selection of MammaPrint Low patients who benefit of 10-year endocrine treatment. van ’t Veer is the Angela and Shu Kai Chan Endowed Chair in Cancer Research and co-leader of the Breast Oncology Program for the UCSF HDFCCC. Abstract GS5-10

2:30 pm to 2:45 pm CT

Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2–Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD, is first author and presenter for this study about new options for treatment of metastatic breast cancer with TROP2 tumor expression. Abstract GS5-11